STRIDES ARCOLAB & GILEAD CONCLUDES STRATEGIC ARV (ANTI RETRO VIRAL) DEAL

Strides Arcolab Ltd has announced that the company has signed a non-exclusive license and technical transfer agreement with US based bio-pharmaceutical Company, Gilead Sciences. This agreement will enable the company to manufacture and distribute generic versions of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Vlread (tenofovir disoproxil fumarate). This agreement provides for the manufacture and distribution of a new generation first line therapy in over 90 countries under the Gilead Access Program. This country classification is rated according to the Human Development Index and includes high prevalence focus countries in Africa and Asia including India. Equity Bulls (http://www.equitybulls.com/admin/news2006/news_det.asp?id=573)